254 related articles for article (PubMed ID: 31429794)
1. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.
Tesser J; Kafka S; DeHoratius RJ; Xu S; Hsia EC; Turkiewicz A
Arthritis Res Ther; 2019 Aug; 21(1):190. PubMed ID: 31429794
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
[TBL] [Abstract][Full Text] [Related]
4. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
[TBL] [Abstract][Full Text] [Related]
6. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Baker D; Ishii Y; Yoshinari T;
Mod Rheumatol; 2016 Jul; 26(4):481-90. PubMed ID: 26474192
[TBL] [Abstract][Full Text] [Related]
8. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
Weinblatt ME; Westhovens R; Mendelsohn AM; Kim L; Lo KH; Sheng S; Noonan L; Lu J; Xu Z; Leu J; Baker D; Bingham CO;
Ann Rheum Dis; 2014 Dec; 73(12):2152-9. PubMed ID: 24001888
[TBL] [Abstract][Full Text] [Related]
9. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
10. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Emery P; Fleischmann RM; Doyle MK; Strusberg I; Durez P; Nash P; Amante E; Churchill M; Park W; Pons-Estel B; Xu W; Xu S; Wu Z; Hsia EC
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1732-42. PubMed ID: 23861303
[TBL] [Abstract][Full Text] [Related]
11. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
[TBL] [Abstract][Full Text] [Related]
12. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
[TBL] [Abstract][Full Text] [Related]
13. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
[TBL] [Abstract][Full Text] [Related]
15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
16. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study.
Tanaka Y; Harigai M; Takeuchi T; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Kanazawa M; Oba T; Yoshinari T; Baker D;
Ann Rheum Dis; 2012 Jun; 71(6):817-24. PubMed ID: 22121129
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
Taylor PC; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Mack M; Kremer J
J Rheumatol; 2011 Dec; 38(12):2572-80. PubMed ID: 22089463
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
Huffstutter JE; Kafka S; Brent LH; Matucci-Cerinic M; Tang KL; Chevrier M; Sprabery T; DeHoratius RJ
Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
[TBL] [Abstract][Full Text] [Related]
20. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU
Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
